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Ovarian cancer is often diagnosed at advanced stages of the
disease. Despite improvements in chemotherapy and surgical
treatment, the overall 5-year survival rate for patients with epithe-
lial ovarian cancer remains at only 35% (Landis et al, 1998).
Overall, the molecular changes that underlie the initiation and
development of this tumour are poorly understood. A greater
understanding of these complex molecular events could lead to
improvements in screening techniques and may ultimately provide
new targets for chemotherapeutic drugs and gene therapy. 
The transforming growth factor-β (TGFβ ) family is a group of
structurally related polypeptides with diverse functions. There are
at least 3 highly homologous TGFβ isoforms in humans: TGFβ 1,
TGFβ 2 and TGFβ 3. TGFβ 1 is the best-characterized TGFβ
isoform, and is known to regulate cell proliferation and differenti-
ation, and can inhibit or stimulate cell growth in different cell
types (Yan et al, 1994). TGFβ 1 is also known to have an important
role in extracellular matrix deposition, cell adhesion, angiogenesis,
and immune function (Polyak, 1996). In most cell types, TGFβ is
a potent inhibitor of cell growth, arresting cell cycle progression in
late G1 phase. This growth suppression is associated with the
increased expression or activities of several cyclin-
dependent kinase inhibitors, including p15, p21 and p27 (Rich 
et al, 1999). Critical mutations in the TGFβ pathway should also
lead to the loss of the ability of the cell to undergo apoptosis.
TGFβ is therefore a putative tumour suppressor gene and diminished
responsiveness to TGFβ is a common feature of epithelial cancers. 
TGFβ 1 is secreted from most cells in its latent form, by the non-
convalent association with latency-associated protein (LAP). LAP
is a homodimer formed from the pro-peptide region of TGFβ 1,
and is in turn linked to the latent TGFβ -binding protein (LTBP).
Latent-TGFβ 1 must undergo cleavage from this complex in order
to become activated. LTBP targets latent TGFβ 1 to the extracel-
lular matrix, where it interacts with the insulin-like growth factor
II receptor (IGFIIR), itself a putative tumour suppressor gene
(Munger et al, 1997). It is thought that IGFIIR orientates latent-
TGFβ 1 for proteolytic cleavage. Once activated, homodimeric
TGFβ 1 binds to the constitutively active TGFβ receptor type II
(TGFβ RII). This binding is necessary for recruitment and activa-
tion of TGFβ receptor type I (TGFβ RI). The TGFβ RII phosphory-
lates specific serine residues immediately upstream of the
serine-threonine kinase of TGFβ RI, resulting in its activation. An
anchor protein called Smad anchor for receptor activation (SARA)
then recruits Smad2 and Smad3 to the activated TGFβ RI
(Tsukazaki et al, 1998). Smad2 and Smad3 become transiently
associated with, and phosphorylated by, the activated TGFβ RI.
This association results in the formation of a complex with Smad4.
This Smad complex migrates to the nucleus, and recruits other
transcription factors and stimulates the expression of specific
target genes. The escape from its role in growth inhibition may
allow TGFβ to act in tumour cells to promote tumourigenicity
through its other functions, such as by the stimulation of angiogen-
esis, extracellular matrix deposition and immunosuppression.
Therefore defects in the TGFβ pathway might be expected to be
associated with cancer development, and mutations in the coding
sequence of mature TGFβ 1 have been reported in ovarian
(Cardillo et al, 1997a), breast (Cardillo et al, 1997b), and colon
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IGFIIR has been proposed as a putative tumour suppressor gene
due to its ability to bind and degrade the mitogen IGF-II, promote
activation of the growth inhibitor TGFβ , and regulate the targeting
of lysosomal enzymes (Jirtle et al, 1994). Loss of heterozygosity
(LOH) at the IGFRII locus at 6q26-27 is common in hepato-
cellular carcinomas and point mutations occur in the remaining
IGFIIR allele in 25% of hepatocellular carcinomas with LOH,
supporting the role of IGFIIR as a tumour suppressor gene (de
Souza et al, 1995a, 1995b). LOH at the IGFIIR locus is also a
common occurrence in ovarian cancer (Cooke et al, 1996), and
appears to be an early event in tumourigenesis development
(Chenevix-Trench et al, 1997), but mutations in this gene have not
been reported in epithelial ovarian carcinoma. 
Both TGFβ RII and TGFβ RI are transmembrane serine/
threonine kinase receptors, and epithelial cells lacking them are
completely unresponsive to the inhibitory response of TGFβ 1
(Chen and Derynck, 1994). Several studies have shown that insen-
sitivity to the growth inhibitory effects of TGFβ are most
commonly due to alterations of the TGFβ RII gene. Loss of expres-
sion of TGFβ RII protein is a frequent event in prostate cancer and
reintroduction of wild-type TGFβ RII into prostate cancer cells
lacking TGFβ RII restores the growth inhibitory response by
exogenous TGFβ 1 (Gerdes et al, 1998; Guo and Kyprianou,
1998). In their study of ovarian cancer, Lynch et al (1998) found
mutations in 6 of 24 samples (25%) in TGFβ RII. These mutations
included 4 missense mutations within the highly conserved
serine/threonine kinase domain, 1 missense mutation within the
transmembrane domain, and a single frameshift mutation in the
poly(A) microsatellite region. Mutations in TGFβ RII have also
been reported in squamous carcinoma of the head and neck
(Garrigue-Antar et al, 1995; Wang et al, 1997). 
A recent report by Wang et al (2000) looked at components of
the TGFβ signal transduction pathway, and screened for mutations
in TGFβ RI, TGFβ RII, Smad2 and Smad4. Unlike Lynch et al
(1998), they did not find exonic mutations in TGFβ RII. However,
a frameshift mutation in exon 5 of TGFβ RI in 10 of 32 tumour
samples (31.3%) was identified. This mutation was associated
with the absence of TGFβ RI expression. 
It has been proposed that IGFIIR, TGFβ 1, and TGFβ RII 
function as a unit, and that somatic loss of function mutations 
in any 1 subunit could lead to disruption of the TGFβ 1 
growth inhibitory pathway and subsequent loss of cell cycle
control. We screened for mutations in these 3 genes in 25 epithelial
carcinomas. If mutations to these genes were identified, this would
suggest that the TGFβ 1 inhibitory pathway is important in the
development of epithelial ovarian cancer and if these mutations are
mutually exclusive in individual cancers, it would support the
hypothesis that these genes act as a functional unit (Haber and
Fearon, 1998). 
METHODS 
Patient DNA samples 
Tumour samples from 25 women with various stages of ovarian
cancer were analysed. The tumours comprised a range of histolo-
gies: 3 were mucinous, 3 endometrioid, 3 clear cell, 15 serous
and 1 of mixed histology. There were 4 Stage 1, 2 Stage 2, 16
Stage 3 and 3 Stage 4 invasive adenocarcinomas. All patients
were staged at laparotomy, in accordance with the recommenda-
tions of the International Federation of Gynaecology and
Obstetrics (FIGO). Germline (from peripheral blood) and tumour
DNA was isolated as described previously (Chenevix-Trench 
et al, 1992). 
Polymerase chain reaction (PCR) 
PCR primers for the amplification of genomic DNA were either
designed using the DNASTAR Lasergene programme or, in the
case of TGFβ 1 exon 7b (Cardillo and Yap, 1997) and TGFβ RII
(Vincent et al, 1996), derived from the literature (Table 1). Exons
8, 9, 27, 28, 31, 33, 34, 40, 47 and 48 of IGFRII, exons 5, 6 and 7
of TGFβ 1 and exons 3, 5 and 7 of TGFβ RII were examined.
Standard reaction mixtures contained 0.2 mM dNTPs, 0.2 µ M
primers, 1 × PCR buffer, and 2.5 units Qiagen Taq DNA poly-
merase. Primer pairs were generally optimized by systematically
varying annealing temperatures and number of cycles for standard
and ‘touchdown’ PCR protocols (Roux, 1995), as well as by
varying final concentrations of MgCl2 and the addition of Q solu-
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Table 1 PCR primers: sequences and sizes of PCR products 
Gene Exon Forward primer 5′→ 3′ Reverse primer 5′→ 3′ Product size 
IGFIIR 8 TTTTTATTTTGCTTCTTTCAC ACTTGGCCCCTACTGTCC 278 
9 GCTGTAGTTTGGGCTGGTGTTTC CCGGAGGGTCTGATTGTGGT 285 
27 AAGGGGACAACTGTGAGGTGAA TGCAACAAAAGGAAAACGACAAA 252 
28 GGGAGGCCAGGGATACTTTGTC AGCAGCCTGAGGGTGGGGAAGAA 305 
31 AGTTCTGTTCTAGCCTGGGGAGTC CAGGTGAATCGGATGGTGGTTGA 235 
33 GTCCCCATCCTCCACCCTACA TTCCTGGCTCTGCTCATCCTTTTT 249 
34 TGTTTTCTCCGCCTTTCCCTTGTG TCTCCCGTGCCCATCTGAAAACTC 313 
40 CTACCGGACATCCAGCATCATA GAGCCAACCATCGTCAAGCAGTCT 305 
47 TTGGGTCAGTTTTGTGGGGTTTTA ACGGGTGTTGCTTTCCTTTCTG 303 
48 GGGCTCACGTGGTCTCTGCTGTT CATTGCTCTGTGCGTTTCTCA 294 
TGFβ 1 5 TCCCCTATCCCCTGACTCCCACAC CTCCATCCAGGCTACAAGGCTCAC 203 
6 GCCCCTCCCTGCCCCTGAT ACCTTGCTGTACTGCGTGTCC 194 
7a GCCCGCCGCCCGCAGGTC GAGTGGGGGAACGTCAGGGATGGA 374 
7b ACGAGCCTGAGCCCTGA CAGGTCGCCCTGTACAA 203 
TGFβ RI 5 GCCCAACCGAAATGTTAATTC GGTAGAACTGCTTATAGAAT 221 
TGFβ RII 3 TGCAATGAATCTCTTCACTC CCCACACCCTTAAGAGAAGA 240 
5 GGCAGCTGGAATTAAATGATGGGC TGCTCGAAGCAACACATG 255 
7 CCAACTCATGGTGTCCCTTTG TCTTTGGCAATGCCCAGCCTG 250 
BJOC 01-1950 687-691  20/8/01  3:16 pm  Page 688tion. Positive (β -globin) and negative (no template DNA) controls
were included in each PCR run, and amplification of a single band
was confirmed by agarose gel electrophoresis and ethidium
bromide staining. 
Single-stranded conformation polymorphism (SSCP)
analysis 
The PCR products were diluted 1/10 with sterile water. Equal
volumes of diluted sample and 2 × formamide loading buffer were
heated to 95˚C for 3 min to denature the samples, and immediately
placed on ice to prevent DNA strands from reannealing. A 2 µ l
aliquot of each sample was electrophoresed alongside non-
denatured and denatured controls. Altogether 4 different SSCP
conditions were used, with polyacrylamide gels consisting of 8%
or 14% polyacylamide, with or without glycerol (10%). Setting
agents were 15 µ l 25% (w/v) ammonium persulphate and 15 µ l
TEMED for every 10 ml of non-denaturing gel. Electrophoresis
was performed at room temperature (20–24˚C) using 0.5 × TBE
running buffer. Mini gels were electrophoresed at 40 mA for 
10 min, then typically for 50 mA for 2 h. The DNA was visualized
using silver staining in standard conditions. The gels were washed,
transferred to Whatman 3 mm filter paper, dried and stored. 
DNA sequencing 
Tumour samples that gave abnormal SSCP mobility shifts were
re-amplified by PCR from the original DNA sample and purified
with the Wizard PCR Preparations DNA Purification System
(Promega). Genomic DNA from blood samples were also
sequenced, to confirm that any observed sequence variation was
tumour specific. Sequencing was performed with the forward
primer using an Applied Biosystems Model 377 automated
sequencer. Any putative mutations identified by DNA sequencing
were confirmed by re-sequencing a sample of the original DNA
with forward and reverse primers. 
RESULTS 
PCR primers for the IGFIIR gene were designed to cover the exons
that have been reported to date to contain somatic mutations
(exons 27, 28, 31, 40, and 48) (IGFIIR mutation database:
http://www.geneimprint.com/), and for those exons for which
flanking intronic sequences were available (exon 8, 9, 33, 34 and
47). PCR primers for the TGFβ 1 gene were designed to cover the
coding region of the mature protein product, namely exons 5, 6 and
7. In the case of exon 7, primers described in the literature were
also used (Cardillo and Yap, 1997). In the case of the TGFβ RII
gene, exons 3, 5 and 7 were targeted for analysis because they have
been found to be mutation hotspots (Vincent et al, 1996). 
SSCP analysis was carried out on 25 tumour and normal
samples. TGFβ RII was found to contain point mutations in 3
tumours, but not in the corresponding germline DNA (Figure 1,
Table 2). The mutations were all in exon 7, and all 3 were
missense mutations in stage 3 tumours. No mutations were found
in IGFIIR or TGFβ 1. A significant association was identified
between TGFβ RII mutation status and histology (Fisher’s exact
test, P = 0.029). Of the 3 mutations identified, 2 of were found in
3 clear cell tumours examined, but in only 1 (a serous tumour)
out of 22 tumours of other histological types that were 
examined. 
DISCUSSION 
It has been proposed that the IGFIIR, TGFβ 1, and TGFβ RII genes
act as a functional unit to negatively regulate cell proliferation.
Somatic loss of function mutations in any one of these genes could
lead to disruption of the TGFβ growth inhibitory pathway and loss
of cell cycle control. As mutations in any one gene within the func-
tional unit would be sufficient to disrupt this pathway, there would
be little selective pressure to mutate the other genes and so muta-
tions would be expected to be mutually exclusive in individual
cancers (Haber and Fearon, 1998). 
We have identified somatic mutations in the TGFβ RII gene in 3
out of 25 (12%) tumours but no mutations were found in the
IFGIIR or TGFβ 1 genes. The TGFβ RII amino acid sequence is
highly conserved between humans, mice and chickens and all 3
missense mutations occurred at conserved residues (Table 3). 
The Glu∆ 515Asp substitution results in a conservative amino 
acid change and occurs within the functionally important kinase
domain, where point mutations have been previously identified
(Lynch et al, 1998; Garrigue-Antar et al, 1995). The Arg∆ 528Pro
substitution also occurs within this kinase domain, resulting in 
a non-conservative amino acid change, replacing a positively
charged residue with an apolar, uncharged one. X-ray crystallog-
raphy of other serine/threonine kinases suggests that this highly
conserved arginine and preceding conserved glutamate are 
essential for kinase function (Zhang et al, 1994). The Asn∆ 564Tyr
TGFβ pathway and ovarian cancer 689
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Table 2 Somatic mutations of TGFβ RII identified in ovarian carcinomas 
Gene Exon Sample Nucleotide Amino  acid Domain Comment 
changes change
TGFβ RII 7 19 GAG→ GAC Glu∆ 515Asp Kinase Conservative mutation 
7 14 CGT→ CCT Arg∆ 528Pro Kinase Non-conservative mutation 
7 8 AAC→ TAC Asn∆ 564Tyr Adjacent kinase Non-conservative mutation 
Three missense mutations were identified in the TGFβ RII gene. 
AB
Figure 1 DNA sequence electropherogram. Panels A and B are sequence
electropherograms from normal and tumour DNA from sample 14. It shows a
region of exon 7 of the TGFβ RII. The sequence indicates a CGT to CCT
nucleotide change
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non-conservative amino acid replacement, exchanging a polar
uncharged residue to an aromatic non-polar one. These types of
changes are well known to affect the protein folding of many
kinases, often leading to changes in kinase activity or substrate
recognition (Taylor et al, 1992). Functional assays would be neces-
sary to confirm the consequences of these mutations, but given their
nature and location it is likely that they contribute to tumorigenesis.
TGFβ RII mutations were significantly associated with histology,
and mutations occurred in 2 of the 3 clear cell carcinomas exam-
ined. This type of ovarian tumour represents a distinct histological
type where the overall prognosis for patients is poor in comparison
with other histologies. The outcome is largely due to the poor
response to conventional platinum-based chemotherapy such as
cisplatin (Goff et al, 1996; Makar et al, 1995; Tanmella et al, 1998). 
This study identified tumour-specific TGFβ RII sequence alter-
ations in 3 out of 25 (12%) patient samples. Lynch et al (1998),
who performed SSCP analysis of the entire coding region of the
TGFβ RII gene, found TGFβ RII mutations in 6 out of 24 (25%)
epithelial ovarian carcinomas. All 4 missense mutations reported
by Lynch et al (1998) resulted in non-conservative amino acid
substitutions. The relevance of these figures to ovarian carcinoma
overall is unclear because both studies examined relatively small
numbers of tumours, and SSCP has a sensitivity level of approxi-
mately 70% in detecting mutations (Orita et al, 1989). This is of
particular concern if specific common, missense mutations are
refractory to detection by SSCP. In addition, we chose to screen
known gene hotspots, and it is possible that mutations are located
within unscreened exons. Therefore the observed mutation
frequencies should be regarded as minimum estimates. Lynch et al
(1998) also performed immunohistochemistry (IHC) to examine
the expression of TGFβ RII protein. A total of 15 out of 25 (62%)
samples demonstrated complete loss or a significant decrease of
TGFβ RII gene expression. This data suggests that factors other
than mutations in the coding region of this gene may contribute to
loss of protein expression, and thus to tumorigenesis. Such mecha-
nisms could include promoter hypermethylation, genomic muta-
tions outside the coding region affecting transcriptional activation
or errors in post-translational modification. 
We were unable to identify mutations in exon 5 of the TGFβ RI
gene in 11 ovarian cancer cell lines by direct sequence analysis,
and 20 tumour samples by SSCP. This variant causes a significant
change in DNA sequence, which should have been detected by
SSCP or DNA sequence analysis. The discrepancies between our
study and Wang et al (2000) remain unexplained. As larger studies
emerge, correlations between specific histology and mutations in
each of the genes may be seen. 
Other members of the TGFβ functional pathway may also be
targets of mutation since other proteins, in addition to IGFIIR,
TGFβ 1, TGFβ RI and TGFβ RII, are required. Candidates would
include Smad2, Smad4 and p21, which are all mutated in various
types of cancer (ten Dijke and Heldin, 1999). However, the recent
study by Wang et al (2000) would suggest that mutations in Smad2
and Smad4 are rare. While mutations occur relatively frequently in
various members of the pathway, there is currently little data to
determine whether there is also decreased gene expression of these
genes, due to epigenetic mechanisms such as promoter hyperme-
thylation, as has been seen for other tumour suppressor genes.
Examination of key components of the TGFβ functional pathway
in a large series of patient samples would provide vital information
regarding the importance of this pathway in the progression of
ovarian cancer. Demonstration of a relationship between TGFβ RII
mutations and clear cell carcinomas of the ovary would suggest
that the TGFβ pathway is important in the development of this
distinct and aggressive subtype of epithelial ovarian carcinoma.
The possibility of distinct developmental pathways for epithelial
ovarian cancer subtypes has been suggested previously. Somatic
mutations in the PTEN (Obata et al, 1998) and β -catenin (Wright
et al, 1999) genes are found most frequently in endometrioid
ovarian tumours, suggesting that these genes may promote differ-
entiation toward this specific subtype. The results presented here
provide further evidence for the role of distinct developmental
pathways in the progression of epithelial ovarian cancer subtypes. 
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